239 related articles for article (PubMed ID: 15857987)
1. Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential.
Wollmann G; Tattersall P; van den Pol AN
J Virol; 2005 May; 79(10):6005-22. PubMed ID: 15857987
[TBL] [Abstract][Full Text] [Related]
2. Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells.
Wollmann G; Robek MD; van den Pol AN
J Virol; 2007 Feb; 81(3):1479-91. PubMed ID: 17108037
[TBL] [Abstract][Full Text] [Related]
3. Mucin-Like Domain of Ebola Virus Glycoprotein Enhances Selective Oncolytic Actions against Brain Tumors.
Zhang X; Zhang T; Davis JN; Marzi A; Marchese AM; Robek MD; van den Pol AN
J Virol; 2020 Mar; 94(8):. PubMed ID: 32051271
[TBL] [Abstract][Full Text] [Related]
4. Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo.
Connor JH; Naczki C; Koumenis C; Lyles DS
J Virol; 2004 Sep; 78(17):8960-70. PubMed ID: 15308693
[TBL] [Abstract][Full Text] [Related]
5. Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells.
Wollmann G; Rogulin V; Simon I; Rose JK; van den Pol AN
J Virol; 2010 Feb; 84(3):1563-73. PubMed ID: 19906910
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses.
Ahmed M; Cramer SD; Lyles DS
Virology; 2004 Dec; 330(1):34-49. PubMed ID: 15527832
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo.
Cary ZD; Willingham MC; Lyles DS
J Virol; 2011 Jun; 85(12):5708-17. PubMed ID: 21450822
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector.
Wollmann G; Paglino JC; Maloney PR; Ahmadi SA; van den Pol AN
Virology; 2015 Jan; 475():1-14. PubMed ID: 25462341
[TBL] [Abstract][Full Text] [Related]
9. Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes.
Wollmann G; Davis JN; Bosenberg MW; van den Pol AN
J Virol; 2013 Jun; 87(12):6644-59. PubMed ID: 23552414
[TBL] [Abstract][Full Text] [Related]
10. Preferential targeting of vesicular stomatitis virus to breast cancer cells.
Bergman I; Whitaker-Dowling P; Gao Y; Griffin JA
Virology; 2004 Dec; 330(1):24-33. PubMed ID: 15527831
[TBL] [Abstract][Full Text] [Related]
11. Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy.
Muik A; Dold C; Geiß Y; Volk A; Werbizki M; Dietrich U; von Laer D
J Mol Med (Berl); 2012 Aug; 90(8):959-70. PubMed ID: 22286341
[TBL] [Abstract][Full Text] [Related]
12. The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma.
Kimpel J; Urbiola C; Koske I; Tober R; Banki Z; Wollmann G; von Laer D
Viruses; 2018 Mar; 10(3):. PubMed ID: 29498639
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats.
Ebert O; Shinozaki K; Huang TG; Savontaus MJ; García-Sastre A; Woo SL
Cancer Res; 2003 Jul; 63(13):3605-11. PubMed ID: 12839948
[TBL] [Abstract][Full Text] [Related]
14. Association of a cellular 21-kDa transmembrane protein (VAP21) with enveloped viruses.
Yamamoto K; Tochikura TS; Xiao S; Sakurai A; Kawai A
Microbiol Immunol; 1999; 43(5):449-59. PubMed ID: 10449251
[TBL] [Abstract][Full Text] [Related]
15. Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.
Wollmann G; Drokhlyansky E; Davis JN; Cepko C; van den Pol AN
J Virol; 2015 Jul; 89(13):6711-24. PubMed ID: 25878115
[TBL] [Abstract][Full Text] [Related]
16. VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1.
Schache P; Gürlevik E; Strüver N; Woller N; Malek N; Zender L; Manns M; Wirth T; Kühnel F; Kubicka S
Gene Ther; 2009 Jul; 16(7):849-61. PubMed ID: 19369968
[TBL] [Abstract][Full Text] [Related]
17. LuIII parvovirus selectively and efficiently targets, replicates in, and kills human glioma cells.
Paglino JC; Ozduman K; van den Pol AN
J Virol; 2012 Jul; 86(13):7280-91. PubMed ID: 22553327
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.
Hadaschik BA; Zhang K; So AI; Fazli L; Jia W; Bell JC; Gleave ME; Rennie PS
Cancer Res; 2008 Jun; 68(12):4506-10. PubMed ID: 18559493
[TBL] [Abstract][Full Text] [Related]
19. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways.
Paglino JC; van den Pol AN
J Virol; 2011 Sep; 85(18):9346-58. PubMed ID: 21734048
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of Sindbis virus-induced intrinsic interference with vesicular stomatitis virus replication.
Hunt JM; Marcus PI
J Virol; 1974 Jul; 14(1):99-109. PubMed ID: 4365326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]